Efficacy and Safety of Deep Sea Water on the Blood Glucose Level
A 8-weeks, Randomized, Double-blind, Placebo-Controlled, Cross-Over Clinical Trials to Evaluated the Efficacy and Safety of Deep Sea Water on Blood Glucose Level
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fasting plasma glucose concentration of 100-140 mg/dL or 2h-postprandial plasma glucose concentration of 140 ~199 mg/dL
Exclusion Criteria:
- Patients with type 1 or type 2 diabetes
- HbA1c ≥9.0%
- Weight decreased by more than 10% within past 3 months
- Have clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, hepatic biliary system, kidney and Urinary system, neuropsychiatry, musculoskeletal, inflammatory and hematologic malignancies, gastrointestinal disorders, etc.
- Hypoglycemic agent, obesity medicine, lipid lowering agent within past 6 months or functional food within past 2 month
- Subjects who have taken corticosteroid within past 1 months
- History of alcohol or substance abuse
- Participation in any other clinical trials within past 2 months
Laboratory test by show the following results
- Serum AST (aspartate aminotransferase) or ALT (alanine aminotransferase) > 2 times the upper limit of normal range
- Serum Creatinine > 2.0 mg/dl
- Pregnancy or breast feeding
- If a woman of childbearing doesn't accept the implementation of appropriate contraception
- Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DSW (deep sea water) group
DSW, 440 ml/day for 8 weeks
|
Deep sea water 440 ml/day for 8 weeks
|
|
Placebo Comparator: Placebo group
Placebo, 440 ml/day for 8 weeks
|
Placeob water 440 ml/day for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of blood glucose
Time Frame: Baseline, 8 weeks
|
Concentration of fasting and postprandial glucose during OGTT (oral glucose tolerance test) were assessed before and after the intervention
|
Baseline, 8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of blood insulin
Time Frame: Baseline, 8 weeks
|
Concentration of blood insulin were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
C-pepetide
Time Frame: Baseline, 8 weeks
|
Concentration of C-peptide were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
HbA1c
Time Frame: Baseline, 8 weeks
|
Concentration of HbA1c were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
Homeostatic model assessment - insulin resistance (HOMA-IR)
Time Frame: Baseline, 8 weeks
|
Concentration of HOMA-IR were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
Total cholesterol
Time Frame: Baseline, 8 weeks
|
Concentration of total cholesterol were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
Triglyceride
Time Frame: Baseline, 8 weeks
|
Concentration of triglyceride were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
HDL-cholesterol
Time Frame: Baseline, 8 weeks
|
Concentration of HDL-cholesterol were assessed befor and after the intervention
|
Baseline, 8 weeks
|
|
LDL-cholesterol
Time Frame: Baseline, 8 weeks
|
Concentration of LDL-cholesterol were assessed befor and after the intervention
|
Baseline, 8 weeks
|
|
Weight
Time Frame: Baseline, 8 weeks
|
Concentration of weight were assessed befor and after the intervention
|
Baseline, 8 weeks
|
|
BMI
Time Frame: Baseline, 8 weeks
|
Concentration of BMI were assessed before and after the invervention
|
Baseline, 8 weeks
|
|
Body fat mass
Time Frame: Baseline, 8 weeks
|
Concentration of body fat mass were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
Percent of body fat mass
Time Frame: Baseline, 8 weeks
|
Concentration of percent of body fass mass were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
Waist circumference
Time Frame: Baseline, 8 weeks
|
Concentration of waist circumference were assessed before and after the intervention
|
Baseline, 8 weeks
|
|
Waist-hip ratio (WHR)
Time Frame: Baseline, 8 weeks
|
Concentration of WHR were assessed before and after the intervention
|
Baseline, 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTCF2_2016_DSW
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.